Clinical Trials on Severe Combined Immunodeficiency Disease

Total 5542 results

National Institute of Allergy and Infectious Diseases...

Recruiting

Evaluation of Patients With Immune Function Abnormalities

Chronic Granulomatous Disease (CGD) | X-Linked Severe Combined Immune Deficiency (XSCID) | Leukocyte Adhesion Deficiency 1 (LAD) | Graft Versus Host Disease (cGvHD)

United States
Chiesi Farmaceutici S.p.A.

Completed

Registry Study of Revcovi Treatment in Patients With ADA-SCID

Severe Combined Immunodeficiency | Adenosine Deaminase Deficiency

United States
Emory University

Completed

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

Severe Combined Immunodeficiency | T-Cell Immune Deficiency Diseases

United States
Great Ormond Street Hospital for Children NHS Foundation...

Completed

Gene Therapy ADA Deficiency

Adenosine Deaminase Deficiency

United Kingdom
Neena Kapoor, M.D.

Terminated

SCID Bu/Flu/ATG Study With T Cell Depletion

Severe Combined Immunodeficiency

United States
University of California, San Francisco

Completed

Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population

Severe Combined Immunodeficiency | T Cell Lymphocytopenia

United States
Assistance Publique - Hôpitaux de Paris

Terminated

Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID) (CD45RA)

Combined Immunodeficiencies

France
National Institute of Allergy and Infectious Diseases...
National Center for Advancing Translational Sciences (NCATS); Primary Immune...

Enrolling by invitation

Patients Treated for SCID (1968-Present)

ADA-SCID | Omenn Syndrome | SCID | Reticular Dysgenesis | XSCID | Leaky SCID

United States, Canada
Paul Szabolcs

Enrolling by invitation

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases (BOLT+BMT)

Chronic Granulomatous Disease (CGD) | Wiskott-Aldrich Syndrome | Severe Chronic Neutropenia | Severe Combined Immunodeficiency (SCID) | Immunodeficiency With Predominant T-cell Defect, Unspecified | Hyper IgE Syndromes | Hyper IgM Deficiencies | Mendelian Susceptibility to Mycobacterial Disease | Common...

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Human Immunodeficiency Virus | Dengue Fever | Dengue Hemorrhagic Fever

Brazil
Ann & Robert H Lurie Children's Hospital of Chicago

Unknown

Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases (SIDS)

Severe Immunodeficiency Diseases

United States
National Human Genome Research Institute (NHGRI)

Withdrawn

Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents

ADA-SCID
Grifols Therapeutics LLC

Completed

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Common Variable Immunodeficiency | Severe Combined Immunodeficiency | Wiskott-Aldrich Syndrome | Agammaglobulinemia | Immunologic Deficiency Syndrome

Canada, United States
University Hospital, Montpellier

Recruiting

Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit (SPYSI)

Severe Infection | Severe Immune Deficiency

France
Centre Leon Berard

Recruiting

Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation (EVAADE)

Myelodysplastic Syndromes | Severe Combined Immunodeficiency | Acute Leukemia | Haematological Malignancy | Hemoglobinopathy in Children | Bone Marrow Aplasia

France
Centre Leon Berard

Withdrawn

A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts (EVAADE)

Myelodysplastic Syndromes | Severe Combined Immunodeficiency | Acute Leukemia | Haematological Malignancy | Hemoglobinopathy in Children | Bone Marrow Aplasia

France
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Cord Blood Stem Cell Transplantation Study (COBLT)

Neoplasms | Myelodysplastic Syndromes | Hematologic Diseases | Leukemia | Severe Combined Immunodeficiency | Fanconi Anemia | Anemia, Aplastic | Hematopoietic Stem Cell Transplantation
Nanfang Hospital of Southern Medical University
The Affiliated Hospital of Qingdao University; Sun Yat-Sen Memorial Hospital... and other collaborators

Recruiting

VAH Versus VA for Salvage Therapy of R/R-AML

Venetoclax Combined With Azacitidine Plus Homoharringtonine | Venetoclax Combined With Azacitidine

China
Assistance Publique - Hôpitaux de Paris

Recruiting

Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction (LEONARD)

Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Mahidol University

Completed

Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN)

Dengue Hemorrhagic Fever

Thailand
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

Dengue Hemorrhagic Fever

United States
Columbia University

Unknown

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Severe Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | Osteopetrosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Terminated

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Genetic Disorder | Severe Aplastic Anemia | Immunodeficiency Syndrome

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Yellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Indonesia, Philippines, Malaysia, Thailand, Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever | Dengue Hemorrhagic Fever

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Shock Syndrome

Puerto Rico
Sanofi

Completed

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome

Dengue Fever

Bangladesh
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras

Clinical Trials on Severe Combined Immunodeficiency Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations